ProVen VCT
Other
Active
London, United Kingdom
20
3M
20
0.80
11
- Areas of investment
Summary
In 1996 was created ProVen VCT, which is appeared as Corporate Investor. The leading representative office of defined Corporate Investor is situated in the London. The company was established in Europe in United Kingdom.
The top activity for fund was in 2007. The usual things for fund are deals in the range of 5 - 10 millions dollars. Comparing to the other companies, this ProVen VCT performs on 31 percentage points more the average number of lead investments. Speaking about the real fund results, this Corporate Investor is 15 percentage points less often commits exit comparing to other organizations. The fund is constantly included in less than 2 deals per year. The increased amount of exits for fund were in 2014.
The typical case for the fund is to invest in rounds with 1-2 participants. Despite the ProVen VCT, startups are often financed by Oxford Capital Partners, Amadeus Capital Partners, West Deutsche Landesbank Girozentrale. The meaningful sponsors for the fund in investment in the same round are Beringea, West Deutsche Landesbank Girozentrale, Temasek Holdings. In the next rounds fund is usually obtained by Scottish Equity Partners, Triathlon Medical Venture Partners, New Science Ventures.
We can highlight the next thriving fund investment areas, such as Health Care, Financial Services. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. The fund has no exact preference in some founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight BioVex, Abzena plc, Altacor. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United Kingdom.
Investor highlights
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 20
- Lead investments
- 0
- Exits
- 11
- Rounds per year
- 0.80
- Investments by industry
- Biotechnology (5)
- Advertising (5)
- Medical (4)
- Health Care (3)
- Manufacturing (3) Show 36 more
- Investments by region
-
- United Kingdom (18)
- United States (1)
- Peak activity year
- 2007
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 19
- Avg. valuation at time of investment
- 60M
- Group Appearance index
- 0.25
- Avg. company exit year
- 13
- Avg. multiplicator
- 7.51
- Strategy success index
- 0.30
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| BioVex | 06 Oct 2003 | Biotechnology, Health Care, Medical | Late Stage Venture | 23M | England, United Kingdom, United Kingdom |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.